SESSIONS & ReSS LIVE!
The Ultimate Streaming Experience

Scientific Sessions 2017

Scientific Sessions: November 11–15

Resuscitation Science Symposium: November 11–13

Anaheim, California

What to Expect

Top presentations from AHA's Scientific Sessions 2016 and Resuscitation Science Symposium 2016 will be live-streamed during the conference, and will remain available for viewing up to 30 days after the conference.

Purchase a live streaming pass today for as little as $99 and watch today's top cardiovascular and resuscitation experts speak on the newest developments in your field.

Big names and big science await YOU in New Orleans this November, even if you can't be there.


DON'T MISS your opportunity to watch the world's best cardiovascular and resuscitation science from the comfort of your home or office.


 

Pricing

Standard Packages (Single Viewer)

  • Single Day: $99
     
  • Two Days: $179
     
  • Three Days: $249
    • NOTE: Select any 3 days, add 4th day for FREE!
Group Packages (2 to 19 Viewers)

  • Single Day: $199
     
  • Two Days: $399
     
  • Three Days: $499
    • NOTE: Select any 3 days, add 4th day for FREE!
Institutional Packages (20+ Viewers)

  • Single Day: $999
     
  • Two Days: $1,499
     
  • Three Days: $1,999
    • NOTE: Select any 3 days, add 4th day for FREE!

Scheduled Programming

Scientific Sessions

The following schedule is a guide only. Available speakers and presentations are subject to change pending presenter's agreement to AHA recording release.

MAIN EVENT 1 Sunday, Nov. 13: Scientific Sessions

Opening Session
Introduction by Nancy Brown, CEO, American Heart Association
1:00 p.m. – 3:00 p.m. Welcome and Presidential Address
Steven R. Houser, Philadelphia, PA

Chairman’s Award
Sidney Smith, Jr., Chapel Hill, NC

Distinguished Scientist Recognition
Basic Research Prize

Elizabeth McNally, Chicago, IL

Clinical Research Prize
Joseph Ornato, Richmond, VA

Population Research Prize
Emelia Benjamin, Framingham, MA

Eugene Braunwald Academic Mentorship Award
Eric Olson, Dallas, TX

Research Achievement Award
Robert Califf, Silver Springs, MD

Joseph A. Vita Award
Christine Seidman, Boston, MA

Scientific Sessions Program Chair’s Opening Remarks
Frank Sellke, Providence, RI

Lewis A. Conner Memorial Lecture
Robert Califf, Silver Springs, MD



MAIN EVENT 1 Sunday, Nov. 13: Scientific Sessions

Late Breaking Clinical Trials: Big Trials for Big Questions
Moderators: Carl Pepine, MD; Donna Arnett, MD, BSN FAHA; James De Lemos, MD
3:45 p.m. – 4:03 p.m. Effects of Ticagrelor Compared With Clopidogrel in Patients With Peripheral Artery Disease (EUCLID)
Manesh Patel, MD
4:03 p.m. – 4:08 p.m. Discussant: Effects of Ticagrelor compared With Clopidogrel in patients With Peripheral Artery Disease
Carl Pepine, MD
4:13 p.m. – 4:31 p.m. Cardiovascular Outcomes With Celecoxib vs. Ibuprofen or Naproxen: The Precision Trial
Steven Nissen, MD, FACC
4:31 p.m. – 4:36 p.m. Discussant: Cardiovascular outcomes With Celecoxib vs. Ibuprofen or Naproxen
Elliott Antman, MD, FAHA
4:41 p.m. – 4:53 p.m. The Effect of Blood Pressure and Cholesterol Lowering on Cognition
Jackie Bosch, PhD
4:53 p.m. – 4:56 p.m. Discussant: The Effect of blood pressure and cholesterol lowering on Cognition
Philip Gorelick MD, MPH, FAHA
4:56 p.m. – 5:08 p.m. Short- and Long-Term Effect of Immediate Vasodilator Therapy in Acutely Decompensated Heart Failure:Results of the TRUE-AHF Trial
Milton Packer, MD
5:08 p.m. – 5:11 p.m. Discussant: Short- and Long-TermEffect of Immediate Vasodilator Therapy in Acutely Decompensated Heart Failure: Results of the TRUE-AHF Trial
Clyde Yancy, MD, FAHA



MAIN EVENT 2 Sunday, Nov. 13: Scientific Sessions

Main Event Session: Cardiac Regeneration — Where Are We Now?
Moderators: Yoshihiko Saito, MD, FAHA; Robert Bolli, MD
4:00 p.m. – 4:15 p.m. Induced Pluripotent Stem Cells - Clinical Applications
Joseph Wu, MD, PhD
4:15 p.m. – 4:30 p.m. Stem Cell Therapy for Ischemic and Vascular Disease
Andreas Zeiher, MD
4:30 p.m. – 4:45 p.m. Regenerative Approaches for Chronic Heart Failure
Joshua Hare, MD, FAHA
4:45 p.m. – 5:00 p.m. What Does the Future Hold for Regenerative Therapies?
Philippe Menasche, MD, PhD

The following schedule is a guide only. Available speakers and presentations are subject to change pending presenter's agreement to AHA recording release.

MAIN EVENT 2 Monday, Nov. 14: Scientific Sessions

Clinical Science Special Report: Risk Reduction Strategies on a Global Stage
Moderators: Mark Huffman; George Mensah, MD, FACC, FAHA; Valentin Fuster, MD, PhD, FAHA
9:00 a.m. – 9:12 a.m. A Comprehensive Lifestyle Intervention in Patients With Coronary Artery Disease: Main Results of the Randomized Multicenter Response 2 Trial
Ron Peters
9:12 a.m. – 9:15 a.m. Discussant: A Comprehensive Lifestyle Intervention In Patients With Coronary Artery Disease: Main Results Of The Randomized Multicenter Response 2 Trial
Eric Peterson, MD
9:15 a.m. – 9:27 a.m. A Cluster Randomized Trial of a Comprehensive Approach for Hypertension Control in Low-income Patients in Argentina
Jiang He, MD, PhD FAHA
9:27 a.m. – 9:30 a.m. Discussant: A Cluster Randomized Trial of a Comprehensive Approach for Hypertension Control in Low-income Patients in Argentina
Otavio Berwanger, MD
9:30 a.m. – 9:42 a.m. A Randomized Trial of Community Health Action to Encourage healthy Behaviors: The Grenada Heart Project -CHANGE Trial
Sameer Bansilal, MD, MS
9:42 a.m. – 9:45 a.m. Discussant: A Randomized Trial of Community Health Action To Encourage healthy Behaviors: The Grenada Heart Project -CHANGE Trial
Zubin Eapen, MD
9:45 a.m. – 9:57 a.m. Large Scale Analysis of Lifetime Risk of Cardiovascular Disease in Europe and Population Attributable Risk of Cardiovascular Risk Factors for the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) Investigators
Stefan Blankenberg, MD
9:57 a.m. – 10:00 a.m. Discussant: Large Scale Analysis of Lifetime Risk of Cardiovascular Disease in Europe and Population Attributable Risk of Cardiovascular Risk Factors. For the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) Investigators
Donald Lloyd-Jones, MD


MAIN EVENT 1 Monday, Nov. 14: Scientific Sessions

Main Event Session: Precision Medicine 2016
Moderators: Steve Houser, PhD; Ivor Benjamin, MD, FAHA, FACC
9:00 a.m. – 9:15 a.m. Precision Medicine for the Population
Dan Roden, MD
9:15 a.m. – 9:30 a.m. Diagnosing Disease With New Genomic Technology
Euan Ashley, MB, Dphil, MRCP
9:45 a.m. – 10:00 a.m. Personalizing Cardiovascular Surgery: 3D Printing and Simulation
Jamil Aboulhosn, MD, BS
10:00 a.m. – 10:15 a.m. What's in It for Me? The Patient Perspective on Precision Medicine
Sharon Terry, MA, BA


MAIN EVENT 1 Monday, Nov. 14: Scientific Sessions

Late Breaking Clinical Trials: Pioneering the Future of HeART Interventions
Moderators: Timothy Gardner, MD, FAHA; Manesh Patel, MD; Laura Mauri, MD, MSc
10:45 a.m. – 10:57 a.m. Randomized Comparison of Single Versus Bilateral Internal Mammary Artery Grafting in 3102 Patients: Effects on Major Cardiovascular Outcomes After Five Years Follow Up
David Taggard, MD
10:57 a.m. – 11:00 a.m. Discussant: Randomized comparison of single versus bilateral internal mammary artery grafting in 3102 patients: Effects of major cardiovascular outcomes After five years of follow up
Frank Sellke, MD, FAHA
11:00 a.m. – 11:12 a.m. The FUnctional Testing Underlying Coronary REvascularization (FUTURE) Study: A "Real World" Comparison of Fractional Flow Reserve-guided Management versus Conventional Management in Multi Vessel Coronary Artery Disease Patients
Gilles Rioufol, MD, PhD
11:12 a.m. – 11:15 a.m. Discussant: The FUnctional Testing Underlying coronary REvascularization (FUTURE) Study: A "real World" Comparison Of Fractional Flow Reserve-guided Management Versus Conventional Management In Multi Vessel Coronary Artery Disease Patients
Herbert Aronow
11:15 a.m. – 11:27 a.m. An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention PIONEER AF-PCI
C Michael Gibson, MS, MD
11:27 a.m. – 11:30 a.m. Discussant: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention PIONEER AF-PCI
Philippe Gabriel Steg, MD
11:30 a.m. – 11:42 a.m. Patients at Intermediate Surgical Risk Undergoing Isolated Interventional or Surgical Aortic Valve Replacement for Severe Symptomatic Aortic Valve Stenosis One Year Results From the German Aortic Valve Registry
Nicolas Werner, MD
11:42 a.m. – 11:45 a.m. Discussant: Patients at intermediate surgical risk undergoing isolated interventional or surgical aortic valve replacement for severe symptomatic aortic valve stenosis One Year results From the German Aortic Valve Registry
Craig Smith


MAIN EVENT 2 Monday, Nov. 14: Scientific Sessions

Main Event Session: Changing Landscape of Acute Coronary Syndrome Care
Moderators: Stefan James, MD, PhD; Roxana Mehran, MD, FAHA, FACC
10:45 a.m. – 11:00 a.m. Changing Epidemiology of ACS - Older Patients and New Problems
Keith Fox, BSC, MB, ChB, FESC, FRCP
11:00 a.m. – 11:15 a.m. High-Sensitivity Biomarkers - Does Help or Hurt With Clinical Care
Benjamin Scirica MD, MPH
11:30 a.m. – 11:45 a.m. Confusion After Reperfusion - Which Drugs When and How Long
Dominick Angiolillo, MD, PhD, FACC, FESC
11:45 a.m. – 12:00 p.m. Mechanical Circulatory Support for ACS and Shock
Charanjit Rihal


MAIN EVENT 1 Monday, Nov. 14; Scientific Sessions

Main Event Session: Life's Sort of Simple 7: Implementing Ideal CV Health Through the Lifespan
Moderators: George Mensah, MD; Lawrence Appel, MD
2:00 p.m. – 2:15 p.m. Behavioral Economics in the Workplace
Anne Thorndike, MD, MPH
2:15 p.m. – 2:30 p.m. Innovations in CV Prevention in Middle Income Countries
Denis Xavier, MD, PhD
2:30 p.m. – 2:45 p.m. Simple 7 Not so Simple: Disparities in Implementation
Lisa Cooper
2:45 p.m. – 3:00 p.m. Practical Solutions for Integrating Physical Activity in the Evolving US Health Care Landscape
Elizabeth Joy, MD
3:00 p.m. – 3:15 p.m. Healthy Dietary Patterns Through the Lifespan
Linda Van Horn, PhD, RD, FAHA


MAIN EVENT 2 Monday, Nov. 14; Scientific Sessions

Main Event Session: Frontiers in Heart Valve Disease
Moderators: Michael Fischbein, MD, PhD; Linda Gillam
2:00 p.m. – 2:15 p.m. The Burden of Valve Disease: Increasing Prevalence, Improved Diagnosis, or Better Therapies?
Patrick O'Gara, MD
2:15 p.m. – 2:30 p.m. Molecular Basis of Valve Disease: What Do We Know in 2016?
Thomas Gleason, MD, FACC, FACS
2:30 p.m. – 2:45 p.m. Imaging Valve Disease: More than Meets the Eye
Mani Vannan
2:45 p.m – 3:00 p.m. Timing of intervention: is it time to rewrite the guidelines in the asymptomatic patient?
Blase Carabello, MD, FAHA
3:00 p.m. – 3:15 p.m. Convergence of open surgical and transcatheter therapies: how to train the valvular interventionist of the future?
Joseph Bavaria


MAIN EVENT 1 Monday, Nov. 14; Scientific Sessions

Main Event Session: What is the Role of PCSK9 Inhibitors in CV Prevention?
Moderators: Anne Goldberg, MD; Karol Watson
3:45 p.m. – 4:00 p.m. LDL's Fundamental Role in Atherosclerosis
Kevin Jon Williams, MD
4:00 p.m. – 4:15 p.m. LDL-C Lowering Drugs for Preventing CV Events
Christopher Cannon, MD, FAHA
4:15 p.m. – 4:30 p.m. PCSK9 Monoclonal Antibody Efficacy and Safety
Vera Bittner, MD
4:30 p.m. – 4:45 p.m. Framework for Using Nonstatins in Clinical Practice
Jennifer Robinson, MD
4:45 p.m. - 5:00 p.m. Introduction to Panel Discussion: Value of PCSK9 Inhibitors
Salim Yusuf, PhD, MBBS



MAIN EVENT 2 Monday, Nov. 14: Scientific Sessions

Clinical Science Special Report: Cell Therapy: Ready for Prime Time?
Moderators: Timothy Henry, MD; Stefanie Dimmeler, PhD; Joseph Wu, MD, PhD, FAHA
3:45 p.m. – 3:57 p.m. Administration of Autologous Bone Marrow Cells for Limb Salvage in Patients With Critical Limb Ischemia: Results of the Multicenter Phase III MOBILE Trial
Michael Murphy, MD, FACS
3:57 p.m. – 4:09 p.m. Administration of ALDH Bright Cells to Patients With Intermittent Claudication: The NHLBI CCTRN PACE Trial
Lem Moyé, PhD, MD
4:09 p.m. – 4:21 p.m. Randomized Comparison of Allogeneic vs Autologous Mesenchymal Stem Cells in Patients With Non-Ischemic Dilated Cardiomyopathy - The POSEIDON-DCM Trial
Joshua Hare, MD, FAHA
4:41 p.m. – 4:33 p.m. The NHLBI TIME Trial: Role of Microvascular Obstruction in 2-Year Clinical and MRI Follow-up
Jay Traverse, MD
4:33 p.m. – 4:43 p.m. Summary Talk on the State of the Science
Andre Terzic, MD
4:43 p.m. – 5:00 p.m. Panel Participants
Doris Taylor, MD; Roberto Bolli, MD; Andre Terzic, MD

The following schedule is a guide only. Available speakers and presentations are subject to change pending presenter's agreement to AHA recording release.


MAIN EVENT 1 Tuesday, Nov. 15: Scientific Sessions

Main Event Session: Acute Pulmonary Embolism in 2016: the Challenge of Rapidly Shifting Paradigms
Moderators: Sanja Misra, MD; Gregory Piazza, MD
9:00 a.m. – 9:15 a.m. Risk Stratification for PE: Identifying the Spectrum of Disease
Gregory Piazza, MD
9:15 a.m. – 9:30 a.m. Evolution or Revolution?: Antithrombotic and Fibrinolytic Therapy for Acute PE
Samuel Goldhaber, MD
9:30 a.m. – 9:45 a.m. Endovascular Intervention for Acute PE: Following the Lead of ACS Care
Akhilesh Sista
9:45 a.m. – 10:00 a.m. Expanding the Playbook: Surgery and Circulatory Support for the Failing PE Patient
Richard Channick, MD, FCCP
10:00 a.m. – 10:15 a.m. Pulmonary Embolism Response Teams: From Novel Strategy to Standard of Care
Christopher Kabrhel, MD


 

MAIN EVENT 2 Tuesday, Nov. 15: Scientific Sessions

Main Event Session: Atrial Fibrillation - Innovating to Improve Outcomes
Moderators: John Camm, MD; Jonathan Piccini, MD, MHSc
9:00 a.m. – 9:15 a.m. Basic Mechanisms of Atrial Fibrillation - Have We Learned Anything in the Last Four Years?
Stanley Nattel, MD
9:15 a.m. – 9:30 a.m. Pharmacology to Occlusion - How Can We Prevent Stroke in 2016?
Richard Page
9:30 a.m. – 9:45 a.m. Is a Cure for Atrial Fibrillation on the Horizon? - Future directions for atrial fibrillation ablation
Hugh Calkins, MD
9:45 a.m. – 10:00 a.m. Can We Find New Drug Targets for Atrial Fibrillation?
Isabelle Van Gelder, MD
10:00 a.m. – 10:15 a.m. Is Prevention as Good as Ablation?
Emelia Bejamin, MD, ScM, FAHA, FACC


 

MAIN EVENT 1 Tuesday, Nov. 15: Scientific Sessions

Late Breaking Clinical Trials: Insights from New Therapeutic Trials for Lipids
Moderators: Anne Goldberg, MD; Raul Santos, MD, PhD; Seth Martin, MD
10:45 a.m. – 10:55 a.m. Inhibition of PCSK9 Synthesis via RNA Interference: 90 Day Data From Orion-1-a Multi-centre Phase-2 Randomized Controlled Trial
Kausik Ray, MD, MPhil, FRCP, FACC, FESC
10:55 a.m. – 10:58 a.m. Discussant: Inhibition of PCSK9 Synthesis via RNA Interference
Borge Nordestgaard, MD, DMSc
10:58 a.m. – 11:08 a.m. Effect of Evolocumab on Progression of Coronary Atherosclerosis in Statin-Treated Patients: A Placebo-Controlled Intravascular Ultrasound Trial
Steven Nissen, MD, FACC
11:08 a.m. – 11:11 a.m. Discussant: Effect of Evolocumab on Progression of Coronary Atherosclerosis in Statin-Treated Patients
Raul Santos, MD, PhD
11:11 a.m. – 11:21 a.m. The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Human ApoA-I, After Acute Myocardial Infarction - The ApoA-I Event Reduction in Ischemic Syndromes I (AEGIS-I) Trial
C. Michael Gibson, MS, MD
11:21 a.m. – 11:24 a.m. Discussant: The safety and tolerability of CSL 112, a reconstituted, infusible, human ApoA-I, After acute myocardial infarction
Philip Barger, MD, PhD, FAHA
11:27 a.m. – 11:37 a.m. Ionis-angptl3-lRx, an Antisense Inhibitor to Angiopoietin-like Protein 3 [angptl3] Reduces Plasma Angptl3 and Lipids in Healthy Volunteers With Elevated Triglycerides
Teresa Brandt, PhD
11:37 a.m. – 11:40 a.m, Discussant: Ionis-angptl3-lRx, An antisense inhibitor to Angiopoietin-like Protein 3 reduces plasma Angptl3 and lipids in healthy volunteers With elevated Triglycerides
Christie Ballentyne, MD
11:43 a.m. – 11:53 a.m. Impact of Infusion of an ApoA-IMilano HDL Mimetic on Regression of Coronary Atherosclerosis in Acute Coronary Syndrome patients: the MILANO-PILOT Study
Stephen Nicholls, MD, PhD
11:53 a.m. – 11:56 a.m. Discussant: Impact of Infusion of an ApoA-IMilano HDL Mimetic on regression of coronary Atherosclerosis in Acute Coronary Syndrome Patients
Daniel Rader, MD


MAIN EVENT 2 Tuesday, Nov. 15: Scientific Sessions

Main Event Session: From Precision to Population: Optimizing Outcomes in HF
Moderators: Eugene Braunwald, MD, FAHA; Nancy Sweitzer, MD, PhD, FACC
11:15 a.m. – 11:30 a.m. Systems Based Quality Programs: Using EMR and Mobile Technology to Improve Care
Colleen McIlvennan, DNP
11:30 a.m. – 11:45 a.m. Evolving Medical Management in HF-REF and HF-PEF: Out With the Old and in With the New?
Karl Swedberg, MD
11:45 a.m. – 12:00 p.m. Big Data: How Do We Solve These Problems?
Gregg Fonarow, MD, FAHA


MAIN EVENT 2 Tuesday, Nov. 15: Scientific Sessions

Distinguished Scientist Lecture
12:30 p.m. – 1:30 p.m. Distinguished Scientist Lecture
Philip Wolf, MD, FAHA


MAIN EVENT 1 Tuesday, Nov. 15: Scientific Sessions

New Approaches to Repair The Damaged Cardiovascular System
Moderators: Mark Creager, MD; Elliott Antman, MD
2:30 p.m. – 2:45 p.m. The burden of Vascular Disease
David Siscovick, MD, MPH
2:45 p.m. – 3:00 p.m. IPS cells to develop new Cardiovascular Drug Therapies
Joseph Wu, MD, PhD, FAHA
3:00 p.m. – 3:15 p.m. From Novel Concept to Clinical Reality
Marc Pfeffer, MD


MAIN EVENT 2 Tuesday, Nov. 15: Scientific Sessions

Main Event Session: Maximizing PAD Outcomes in 2016
Moderators: Alan Hirsch, MD; Sanjay Misra, MD
2:00 p.m. – 2:15 p.m. Peripheral Artery Disease: Understanding the burden of Disease
Jeffrey Berger, MD, MS
2:15 p.m. – 2:30 p.m. Antiplatelet Therapy for PAD: Single, Double, or Triple Therapy
Marc Bonaca, MD
2:30 p.m. – 2:45 p.m. Supervised Exercise and Endovascular Intervention for Claudication: Competing Strategies or Complementary Solutions?
Timothy Murphy, MD, FAHA
2:45 p.m. – 3:00 p.m. Critical Limb Ischemia: At the Crossroads of Surgical and Endovascular Care
Matthew Menard, MD


MAIN EVENT 1 Tuesday, Nov. 15: Scientific Sessions

Main Event Session: Dilemmas at the Forefront of Stable Ischemic Heart Disease Management
Moderators: Gregory Barsness, MD; Mauricio Cohen
3:45 p.m. – 4:00 p.m. Physiology vs. Anatomy: Has the PROMISE been realized?
Pamela Douglas, MD, FAHA
4:00 p.m. – 4:15 p.m. Beyond Goal-Directed Medical Therapy: The Rise of PCSK-9 Inhibitors
Stephen Kopecky, MD
4:30 p.m. – 4:45 p.m. Will "ISCHEMIA" Rescue the Interventional Cardiologist?
Raymond Gibbons, MD, MSc, FAHA
4:45 p.m. – 5:00 p.m. Treatment Beyond Drugs and Revascularization
Timothy Henry, MD

Resuscitation Science Symposium

The following schedule is a guide only. Available speakers and presentations are subject to change pending presenter's agreement to AHA recording release.

Saturday, Nov. 12: Resuscitation Science Symposium

Main Event Session: Future of Trauma and Resuscitation Trial Design
Moderators: Kjetil Sunde; Graham Nichol, MD
8:15 a.m. – 8:30 a.m. Post-Resuscitation Trials- What is Needed?
Niklas Nielsen
8:30 a.m. – 8:45 a.m. Efficient Trial Design: Lessons From NETT
Robert Silbergleit, MD
8:45 a.m. – 9:00 a.m. The Problem With Resuscitation Trials Thus Far
Lance Becker, MD, PhD
9:00 a.m. – 9:15 a.m. Pragmatic Trial Design: Lessons From ROC
Clifton Callaway, MD, PhD


2016 Award Presentations
Moderators: Tom Aufderheide, MD, BS, FACEP, FAHA; Benjamin Abella, MD, MPh, MPhil, FACEP
9:30 a.m. – 9:45 a.m. Lifetime Achievement Award in Cardiac Resuscitation Science
Jerry Nolan, FRCA, FCEM, FRCP, FFICM
9:45 a.m. – 10:00 a.m. Lifetime Achievement Award in Trauma Resuscitation Science
Karim Brohi, MD
10:00 a.m. – 10:15 a.m. Ian G. Jacobs Award for International Group Collaboration to Advance Resuscitation Science: Resuscitation Academy
Thomas Rea, MD, MPH


Best of the Best: Oral Abstract Presentations and Presentation of the Best Abstract Awards for Cardiac and Trauma Resuscitation Science 
Moderator: Rudolph Koster, MD, PhD
10:30 a.m. – 10:45 a.m. NIH-Funded Cardiac Arrest Research: A 10-Year Trend Analysis
Ryan Coute
10:45 a.m. – 11:00 a.m. Impact of Changes in the Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care on Neurologically Intact Survival
Ken Nagao
11:00 a.m. – 11:15 a.m. Evaluation of Prehospital Hypotension Depth-duration Dose and Mortality in Major Traumatic Brain Injury
Daniel W. Spaite
11:15 a.m. – 11:30 a.m. Resuscitative Endovascular Balloon Occlusion of the Aorta versus Aortic Cross Clamping Among Patients With Critical Trauma: A Nationwide Cohort Study in Japan
Toshikazu Abe, MD, MPH


Main Event Session: Long-Term Outcomes: What Matters to Patients
Moderators: Steven Brooks, MHSC, MD, FRCPC; Mary Ann Perberdy, MD, FAHA
2:45 p.m. – 3:00 p.m. Patient-Centered Outcomes After Cardiac Arrest
Kristie Haywood
3:00 p.m. – 3:15 p.m. Patient-Centered Outcomes After Major Trauma
Maureen McCunn, MD
3:15 p.m. – 3:30 p.m. What Mattered to Me After My Cardiac Arrest
Kelly Sawyer, MD, MS
3:30 p.m. – 3:45 p.m. What Mattered to Me After My Traumatic Injury
Bryan McVerry


Oral Abstract: Late-Breaking Resuscitation Science Session
Moderator: Jason Bartos, MD, PhD
4:45 p.m. – 5:00 p.m. Impact of Bystander AED Use on Survival And Functional Outcomes in Shockable Observed Public Cardiac Arrest
Ross Pollack, BS
5:00 p.m. – 5:15 p.m. Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest, a Randomized Controlled Trial
Sebastian Wiberg, MD
5:15 p.m. – 5:30 p.m. FROST-I: A Pilot Multicenter Randomized Trial on the Effectiveness of Different Levels of Cooling in Comatose Survivors of Out-of-hospital Cardiac Arrest
Esteban Lopez-de-Sa, MD

The following schedule is a guide only. Available speakers and presentations are subject to change pending presenter's agreement to AHA recording release.

Sunday, Nov. 13: Resuscitation Science Symposium

Main Event Session: Year In Review
Moderators: Ahamed Idris, MD, FAHA; Maaret Castrén, MD, PhD
9:30 a.m. – 9:50 a.m. Year in Review: Cardiac Arrest
Joseph Ornato, MD
9:50 a.m. – 10:10 a.m. Year in Review: Trauma
Joseph Minei, MD


Main Event Session: Preparing for and Executing Team Resuscitation
Moderators: Saket Girotra, MD, SM; Swee Lim, MBBS
12:00 p.m. – 12:15 p.m. Anticipation of Adult In-Hospital Cardiac Arrest
Dana Edelson, MD, MS
12:15 p.m. – 12:30 p.m. Anticipation of Pediatric In-Hospital Cardiac Arrest
Christopher Bonafide
12:30 p.m. – 12:45 p.m. Code Team Performance and Practice
Gavin Perkins, MD
12:45 p.m. – 1:00 p.m. Team Science and Trauma Care
Elizabeth Hunt, MD, MPH, PhD


Main Event Session: Inhalation Therapies in Resuscitation
Moderators: Michael Fries, MD; Michael Holzer, MD
4:30 p.m. – 4:45 p.m. Inhaled Nitric Oxide in Cardiac Arrest
Cameron Dezfulian, MD
4:45 p.m. – 5:00 p.m. Inhaled Xenon in Cardiac Arrest
Mervyn Maze, MD
5:00 p.m. – 5:15 p.m. Hyperbaric Oxygenation in Traumatic Brain Injury
Gaylan Rockswold
5:15 p.m. – 5:30 p.m. Controlled Oxygenation in Cardiac Arrest
Matthias Riess, MD, PhD

The following schedule is a guide only. Available speakers and presentations are subject to change pending presenter's agreement to AHA recording release.

Monday, Nov. 14: Resuscitation Science Symposium

Main Event Session: Pro-Con Debate on EMS Resuscitation Strategy
Moderators: Sten Rubertsson, MD, PhD; Carolina Hansen, MD
9:30 a.m. – 9:45 a.m. Stay and Play: A Physician Perspective
Pierre Carli
9:45 a.m. – 10:00 a.m. Stay and Play: EMS Perspective
Mark Smyth
10:00 a.m. – 10:15 a.m. Scoop and Run: A Physician Perspective
Daniel Spaite, MD, FACEP
10:15 a.m. – 10:30 a.m. Scoop and Run: EMS Perspective
Bryan Fischberg


Main Event Session: Epidemiology in Cardiac Arrest and Trauma
Moderators: Sarah Murthi, MD; Paul Chan
1:30 p.m. – 1:45 p.m. Global Cardiac Arrest Epidemiology: The PAROS Perspective
Marcus Ong, MD, MPH, FRCSI
1:45 p.m. – 2:00 p.m. Resuscitation Disparities: CPR Training and Survival
Monique Anderson, MD, MHS
2:00 p.m. – 2:15 p.m. Resuscitation Disparities: Neighborhoods and Systems of Care
Marina Del Rios, MD, MS
2:15 p.m. – 2:30 p.m. Trauma Epidemiology and Systems of Care
Brendan Carr, MD, MA


Main Event Session: Brain-Directed Resuscitation
Moderators: Vinay Nadkarni, MD, FAAP, FAHA; Sarah Perman, MD, MSCE
3:15 p.m. – 3:30 p.m. Titrating Post-Arrest Care by EEG
Stephan Mayer, MD, FAHA
3:30 p.m. – 3:45 p.m. Near-Infrared Spectroscopy During CPR
Sam Parnia, MD, PhD
3:45 p.m. – 4:00 p.m. Ischemic Conditioning for Brain Resuscitation
Demetris Yannopoulos, MD
4:00 p.m. – 4:15 p.m. pH Monitoring After Traumatic Injury
Eileen Bulger


Oral Abstracts: Post-arrest Management
Moderator: Michael Kurz, MD
4:45 p.m. – 5:00 p.m. Early Coronary Angiography Is Associated With Improved 30-day Survival in Out-of-hospital Cardiac Arrest Patients Without ST-elevation on First Ecg
Ludvig Elfwén, MD
5:00 p.m. – 5:15 p.m. Post-Resuscitation Hyperoxia and Hypoxia Are Associated With Increased Cardiac Arrest Mortality
Henry Wang, MD
5:15 p.m. – 5:30 p.m. Late Repolarization During Targeted Temperature Management at 33 Degree C vs. 36 Degree C and Risk of Ventricular Arrhythmia in Post Cardiac Arrest Care
Jakob Thomsen, MD